Literature DB >> 24359988

Acute kidney injury in the cancer patient.

G Adam Campbell1, Daniel Hu2, Mark D Okusa2.   

Abstract

Acute kidney injury (AKI) is a frequent and significant complication of cancer and cancer therapy. Cancer patients frequently encounter risk factors for AKI including older age, CKD, prerenal conditions, sepsis, exposure to nephrotoxins, and obstructive physiology. AKI can also be secondary to paraneoplastic conditions, including glomerulonephritis and microangiopathic processes. This complication can have significant consequences, including effects on patients' ability to continue to receive therapy for their malignancy. This review will serve to summarize potential etiologies of AKI that present in patients with cancer as well as to highlight specific patient populations, such as the critically ill cancer patient.
Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AKI; Acute renal failure; Malignancy; Nephrotoxins; Oncology

Mesh:

Substances:

Year:  2014        PMID: 24359988     DOI: 10.1053/j.ackd.2013.08.002

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  23 in total

1.  Concurrent acute spontaneous tumor lysis syndrome complicated with multiple organ failure in a patient with pre-existing undiagnosed lung cancer.

Authors:  Fateme Shamekhi Amiri
Journal:  CEN Case Rep       Date:  2015-04-03

2.  Paraprotein-Related Kidney Disease: Attack of the Killer M Proteins.

Authors:  Mark A Perazella; Kevin W Finkel
Journal:  Clin J Am Soc Nephrol       Date:  2016-12-07       Impact factor: 8.237

3.  Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study.

Authors:  Abhijat Kitchlu; Eric McArthur; Eitan Amir; Christopher M Booth; Rinku Sutradhar; Habeeb Majeed; Danielle M Nash; Samuel A Silver; Amit X Garg; Christopher T Chan; S Joseph Kim; Ron Wald
Journal:  J Natl Cancer Inst       Date:  2019-07-01       Impact factor: 13.506

Review 4.  Major comorbid disease processes associated with increased incidence of acute kidney injury.

Authors:  Salwa Farooqi; Jeffrey G Dickhout
Journal:  World J Nephrol       Date:  2016-03-06

5.  Clinical characteristics of patients with malignancies combined with acute kidney injury.

Authors:  Yongfang Qin; Qian Xu; Tingwei Xu; Hai Yuan; Fengqi Hu
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 6.  Acute kidney injury in cancer patients.

Authors:  Shuiying Liu; Jinyuan Zhao; Feng Wang
Journal:  Clin Exp Nephrol       Date:  2021-09-09       Impact factor: 2.801

7.  Urinary KIM-1 in children undergoing nephrotoxic antineoplastic treatment: a prospective cohort study.

Authors:  Danielle Carvalho Pedrosa; Fernanda Macedo de Oliveira Neves; Gdayllon Cavalcante Meneses; Gabriela Pinheiro Gomes Wirtzbiki; Carlos Artur da Costa Moraes; Alice Maria Costa Martins; Alexandre Braga Libório
Journal:  Pediatr Nephrol       Date:  2015-08-07       Impact factor: 3.714

8.  Capillary rarefaction is more closely associated with CKD progression after cisplatin, rhabdomyolysis, and ischemia-reperfusion-induced AKI than renal fibrosis.

Authors:  Anna Menshikh; Lauren Scarfe; Rachel Delgado; Charlene Finney; Yuantee Zhu; Haichun Yang; Mark P de Caestecker
Journal:  Am J Physiol Renal Physiol       Date:  2019-09-11

9.  A cross-sectional study of chemotherapy-related AKI.

Authors:  Xin Kang; Xizi Zheng; Damin Xu; Tao Su; Ying Zhou; Jing Ji; Qi Yu; Yimin Cui; Li Yang
Journal:  Eur J Clin Pharmacol       Date:  2021-05-15       Impact factor: 2.953

10.  Hospital Admission following Acute Kidney Injury in Kidney Transplant Recipients Is Associated with a Negative Impact on Graft Function after 1-Year.

Authors:  Thiago Corsi Filiponi; Lúcio Roberto Requião-Moura; Eduardo José Tonato; Ana Cristina Carvalho de Matos; Alvaro Pacheco E Silva-Filho; Marcelino de Souza Durão Junior
Journal:  PLoS One       Date:  2015-09-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.